(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.05%) $0.927
(0.18%) $10.86
(0.02%) $0.792
(-0.16%) $92.43
Live Chart Being Loaded With Signals
GENinCode Plc engages in the development and commercialization of clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally...
Stats | |
---|---|
Today's Volume | 708 105 |
Average Volume | 258 242 |
Market Cap | 11.06M |
EPS | £0 ( 2023-09-20 ) |
Next earnings date | ( £0 ) 2024-06-04 |
Last Dividend | £0 ( N/A ) |
Next Dividend | £0 ( N/A ) |
P/E | -1.150 |
ATR14 | £0.219 (3.19%) |
GENinCode plc Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
GENinCode plc Financials
Annual | 2022 |
Revenue: | £1.43M |
Gross Profit: | £632 000 (44.20 %) |
EPS: | £-0.0580 |
Q2 | 2023 |
Revenue: | £950 000 |
Gross Profit: | £293 000 (30.84 %) |
EPS: | £-0.0365 |
Q1 | 2023 |
Revenue: | £475 000 |
Gross Profit: | £233 500 (49.16 %) |
EPS: | £-0.0183 |
Q4 | 2022 |
Revenue: | £766 000 |
Gross Profit: | £219 000 (28.59 %) |
EPS: | £-0.0337 |
Financial Reports:
No articles found.
GENinCode plc
GENinCode Plc engages in the development and commercialization of clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company's molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a patented genetic test to help user to adopt cardiovascular prevention steps; Lipid inCode, a genetic diagnostic test, which analyzes the seven genes associated with familial hypercholesterolemia; SUDD inCode, a genetic test to diagnose the cause of sudden cardiac death and familial heart disease; Thrombo inCode, a genetic test that analyzes 12 genetic variants related to hereditary thrombophilia and the risk of thrombosis; and Thrombo inCode Reproductive Health, a genetic test that offers information related to risk of thrombophilia and associated risks for future pregnancies. GENinCode Plc was incorporated in 2018 and is based in Oxford, the United Kingdom.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators